Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

Overview of attention for article published in Arthritis & Rheumatology, July 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 2,305 followers.

RT @NatRevRheumatol: Secukinumab inhibits joint structural damage in active psoriatic #arthritis through 52 weeks - new study in A&R https…

RT @NatRevRheumatol: Secukinumab inhibits joint structural damage in active psoriatic #arthritis through 52 weeks - new study in A&R https…

Secukinumab Provides Significant & Sustained Inhibition of Joint Structural Damage in Phase III Study of Active PsA https://t.co/Yfo5QDPvuH

RT @NatRevRheumatol: Secukinumab inhibits joint structural damage in active psoriatic #arthritis through 52 weeks - new study in A&R https…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.